Proscia, a US-based digital pathology technology developer, has attracted $23m in a series B round that included Hitachi Ventures, the corporate venturing arm of electronics manufacturer Hitachi.
The round was led by venture capital firm Scale Venture Partners and Proscia said the transaction increased its funding to $35m altogether.
Founded in 2014, Proscia has built a modular digital pathology platform that facilitates artificial intelligence-driven image analysis to help diagnose diseases based on tissue samples. Its first tool, DermAI, examines skin biopsies to classify variants of dermatological diseases.
Proscia will employ the fresh capital to accelerate its growth plans, bolstering headcount across its sales, marketing and customer support teams, expanding its product portfolio and enhancing its underlying AI and data science.
The company raised $1m in a 2016 seed round led by Emerald Development Managers and backed by Robin Hood Ventures, TCP Venture Capital and A-Level Capital.
Flybridge Capital Partners then led an $8.3m series A round for Proscia in 2018 that included Emerald Development, Fusion Fund, Razor’s Edge Ventures and Robin Hood Ventures.